Innovation and research have always been at the core of Lanhine Medical. While our product range may be limited, each one reflects our dedication and expertise. Initially, our primary product was the ultra-breathable mask, which played a crucial role during the pandemic. Although the demand for masks dropped sharply after the pandemic, it was this single product—the ultra-breathable mask—that kept our factory running, allowing us to survive the challenging years from 2022 to 2025.
From Masks to Fever-Reducing Gel: The Rise of Our Second Groundbreaking Product
In 2024, we introduced our second groundbreaking product—fever-reducing gel. Behind this product lies 10 years of continuous exploration and innovation by our research and development team. Initially, the product didn’t attract much attention in the market, but we didn’t give up. Through countless experiments and improvements, our fever-reducing gel gradually gained market recognition and was included in the UN procurement directory this year. This achievement is not only a significant validation of our product but also opens up new opportunities for our growth in the future.
Innovation and R&D Are Never Easy, But We Are Always Moving Forward
Research and innovation are never easy, especially in today’s competitive market. Whether it’s the ultra-breathable mask or the fever-reducing gel, we have always adhered to continuous innovation, focusing on perfecting every detail. Every breakthrough has been made possible through the collective effort of our team and ongoing investment in research and development.
Our ultra-breathable mask continues to be the core product of our factory, and currently, orders for the mask are already scheduled through March to April 2026. This growing market trust is a direct result of our constant improvements in product quality and innovation.
On top of that, we have collaborated with a team of PhD experts to develop a new antimicrobial peptide material. This innovative material uses a chemical synthesis process to overcome the instability of traditional fermented antimicrobial peptides, offering zero-toxicity biological solutions to multiple industries. This technology will further drive our progress in the healthcare sector.
Although our product line is not extensive, we understand that continuous innovation is the key to maintaining our foothold in the market. Moving forward, we are committed to launching more groundbreaking products and showcasing the strength of Lanhine Medical to the world.
Post time: Dec-19-2025